Description
Alpelisib
Each tablet contains: Alpelisib………150 mg
INDICATION
Alpelisib is a kinase inhibitor indicated in combination with Fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR) -positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, advanced or metasta tic breast cancer as detected by an FDA -approved test following progression on or after an endocrine – based regimen.
DOSAGE AND USE
The recommended dose of Alpelisibis 300 mg (two 150 mg film -coated tablets) taken orally, once daily with food. Patients should take their dose of Alpelisib at approximately the same time each day. Swallow Alpelisib tablets whole (tablets should not be chewed, crushed or split prior to swallowing).
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer Alpelisib during Pregnancy and Lactation.
Reviews
There are no reviews yet.